Use access key #2 to skip to page content.
$0.07 0.00 (-6.67%)
10/13/2008 2:43 PM

AtheroGenics, Inc. (AGIX)

CAPS Rating:
**

The Company focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including coronary heart disease, organ transplant rejection, rheumatoid arthritis and asthma.

View Ticker Page (AGIX)

Results 1 - 10 of 21 :   123

Recs

6

Avatar bbmaven (99.85) Submitted: 11/29/06 2:18 PM : Outperform Start Price: $12.48 AGIX Score: -68.18

I agree with others that this is very volatile with significant news expected first quarter 2007 - the stock is likely to be either $6 or $35 by the middle of the spring.

Options prices for April reflect this incredible beta - I sold the April20 cal...

Report this Post Replies: 3 | Reply | Permalink

Recs

4

Avatar eldemonio (< 20) Submitted: 12/28/07 11:13 AM : Outperform Start Price: $1.69 AGIX Score: -58.30

At this point what do you have to lose? The stock has just about bottomed out - if it hasn't quite yet bottomed out, you're only losing .38 at the most. Their failed heart drug AGI 1067 that may make a decent add on therapy for type 2 diabetes is i...

Report this Post Replies: 2 | Reply | Permalink

Recs

3

Avatar thenakedtrader (< 20) Submitted: 3/26/07 6:21 PM : Underperform Start Price: $3.61 AGIX Score: 65.00

Hope springs eternal. Despite the failure of the primary endpt. goals, which spurred a 60+% drop last week, bulls are pinning their hopes on 'promising' secondary goals that will be presented tomorrow at ACC.





I don't hold ou...

Report this Post Replies: 0 | Reply | Permalink

Recs

1

Avatar dbar1954 (< 20) Submitted: 2/20/07 6:04 AM : Outperform Start Price: $11.96 AGIX Score: -65.24

Not for the faint of heart but will very likely explode in about three months. Produces a drug for 'melting' placque from artery walls. It has already been approved in the EU where marketing has started. Likewise, Australia. In the US the drug is in ...

Report this Post Replies: 3 | Reply | Permalink

Recs

1

Avatar sassybottoms (83.68) Submitted: 1/18/07 12:01 AM : Outperform Start Price: $10.80 AGIX Score: -66.27

This drug addresses many of the major problems of chronic inflammation. We have the baby boomers that are going to need this drug and the younger populations. RA and asthma are frequent in children. Could this be a lifelong drug? Still in clinica...

Report this Post Replies: 0 | Reply | Permalink

Recs

1

Avatar IrixGuy (< 20) Submitted: 9/18/07 9:10 PM : Outperform Start Price: $1.75 AGIX Score: -58.45

Watch this baby soar.

Report this Post Replies: 0 | Reply | Permalink

Recs

1

Avatar sbrooks64 (< 20) Submitted: 10/27/07 2:03 PM : Outperform Start Price: $1.65 AGIX Score: -58.00

This stock will double in the next year. It is not for the weak at heart

Report this Post Replies: 0 | Reply | Permalink

Recs

0

Avatar tharlow (76.01) Submitted: 9/20/07 6:52 PM : Underperform Start Price: $1.74 AGIX Score: 58.72

Will be bankrupt soon.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

Avatar mbills2 (68.71) Submitted: 10/17/07 1:02 PM : Underperform Start Price: $1.81 AGIX Score: 58.75

who cares

Report this Post Replies: 0 | Reply | Permalink

Recs

0

Avatar zimn0016 (33.92) Submitted: 9/16/07 11:31 PM : Underperform Start Price: $1.71 AGIX Score: 60.51

There was a reson AGI-1067 was dropped by AZN, it may be novel but it's crap compared to other diabetic meds (really cheap ones).

Report this Post Replies: 0 | Reply | Permalink

Featured Broker Partners